79 results about "Dextran sodium sulfate" patented technology

The present invention provides lactobacillus reuteri for preventing ulcerative colitis. The strain is named as lactobacillus reuteri RAM0101 and deposited on May 27, 2019 at China General Microbiological Culture Collection Center and has a preservation number of CGMCC NO.17853. C57BL/6N mice are used as test objects, dextran sodium sulfate (DSS) is used to induce the mice to form an ulcerative colitis model and the model is also used to investigate effectiveness of the strain in preventing the ulcerative colitis. The lactobacillus reuteri can relieve weight loss, diarrhea, hematochezia and disease activity index (DAI) score of the ulcerative colitis mice induced by the DSS, protects pathological damages of colon tissues of the mice induced by the DSS, can enhance colon tissue epithelial barrier completeness and is also free of toxin and harms.

The invention discloses a model for protecting mouse ulcerative colitis by antibacterial peptide C-BF. Cathelicin-BF has broad-spectrum antibacterial activity, especially for Gram negative bacteria. Inflammatory bowel diseases (IBDs) comprise ulcerative colitis (UC) and Crohn disease (CD), and pathomechanisms of the diseases are not clear yet. A model for inducing the mouse ulcerative colitis by 3% dextran sulphate sodium (DSS) is built; a PBS solution of the C-BF is subjected to rectal injection once per day, the dose of the C-BF is 5mg/kg, the continuous injection time is one week, a mouse is weighed and the body weight data of the mouse is recorded each day during experimental period, and the rectal bleeding and dung forming situations of the mouse are observed. The model is used for making a research on a protection effect on the mouse UC caused by the C-BF.

The invention relates to a method for preparing the protamine and dextran sulfate sodium microcapsule, comprising the following steps: reacting calcium chloride, sodium carbonate, sodium polystyrene sulfonate or polyallylamine hydrochloride, cetyl trimethyl ammonium bromide, PEO20-PPO70-PEO20 triblock copolymer, polydiallyldimethylamine chloride solution with stirring at the temperature of 10 to 80 DEG C to obtain the calcium carbonate microsphere; fully mixing the obtained calcium carbonate microsphere with the protamine water solution, adsorbing the protamine, removing the protamine not to be adsorbed, fully mixing the calcium carbonate microsphere with the protamine withdextran sulfate sodium containing inorganic salt to adsorb dextran sulfate sodium, removing the dextran sulfate sodium not to be adsorbed; alternately adsorbing to obtain the microcapsule with the protamine and dextran sulfate sodium multilayer membrane core-shell structure; dissolving calcium carbonate in ethylenediaminetetraacetic acid sodiumsalt to obtain the protamine and dextran sulfate sodium microcapsule.

The invention provides a method for building a dextran sodium sulphate induced enteritis mouse model. The method includes the following steps: A, choosing female C57BL/6 mice with the weight of 19-21g as the objects to build the mouse model; B, dissolving dextran sulphate sodium salt solution in disinfected drinking water to prepare dextran sulphate sodium salt solution with the weight percentage concentration of 2%, and placing the solution in a water bottle for protecting away from the sun, wherein the solution is prepared when required; C, feeding the chosen C57BL/6 mice in a storageprotect feature (SPF) level animal house, enabling the mice to drink the dextran sulphate sodium salt solution prepared in the step B for six days and then drink the normal drinking water for four days. Accordingly, the chosen C57BL/6 mice are dextran sodium sulphate induced enteritis mouse models. By means of the method for building the dextran sodium sulphate induced enteritis mouse model, death rate of animals is reduced to be zero, and pathology expressions are the same, so that the model is stable, reliable and repeatable.

The invention relates to recombinant human lactoferrin (rhLF) silkworm chrysalis powder as well as a preparation method and application thereof and belongs to the technical field of biological medicines. A recombinant virus is constructed mainly by adopting a silkworm chrysalis baculovirus expression system, the rhLF is expressed with a silkworm chrysalis serving as a bioreactor, the silkworm chrysalis diseased after being inoculated with the recombinant virus is prepared into freeze-dried powder, the activity of the freeze-dried powder is detected by performing antibacterial experiments in vitro, and the freeze-dried powder is poured into the stomach of a mouse to treat the dextran sulphate sodium (DSS) induced ulcerative colitis of the mouse. The analysis on the disease activity index (DAI) of the mouse and the detection on the content of myeloperoxidase (MPO) in the colonic tissue of the mouse show that the rhLF with antibacterial activity is expressed successfully in the silkworm chrysalis, and the rhLF silkworm chrysalis powder has a certain effect of treating the DSS induced ulcerative colitis of the mouse. The preparation method provided by the invention is simple, is low in cost and is used for preparing a novel oral protein medicine.

The invention provides a composition containing resveratrol and used for treating ulcerative colitis. The composition consists of the following components in parts by weight: 1-10 parts of resveratrol, 5-20 parts of a grape seed extract, 10-50 parts of prebiotics and an adhesive which is 2-5% of the total weight of other components, and the binder namely the adhesive is water or an alcohol solution of 80-95%. The components of the composition cooperate for common use, so that the in vivo cell factors can be regulated, and the inflammation can be restrained; and after experiment mice induced with dextran sulfate sodium are intervened with the composition, the symptom of acute colitis is relieved, the weight reduction is restrained, and the colon shrinking degree is obviously improved. The composition preparation is harmonious in color after being brewed and is moderate in mouth feel.

The invention relates to an application of Chinese traditional herb monomer wedelolactone as a drug for treating ulcerative colitis. According to the application, wedelolactone is obtained from Chinese traditional herb material eclipta, and the structure of wedelolactone is determined according to spectrum data. Through intragastric administration of wedelolactone, the body weight change of a model mouse is obviously changed, the length of the colon is increased, the inflammation level of the colon is obviously hanged, the NO content reflecting the inflammation degree of the colon is reduced, the activity of myeloperoxidase (MPO) in the colon tissue is reduced, release of inflammatory factors IL-8 of Caco-2 cells excited byIL-1beta is inhibited in vitro. The results of in-vivo and in-vitro experiments show that wedelolactone under certain dosage can obviously inhibit release of the inflammatory factors of the colon tissue, so that the acute ulcerative colitis of the mouse caused by dextran sulphate sodium salt (DSS) can be obviously improved, and therefore, wedelolactone has a novel application as a drug for treating or improving ulcerative colitis.

The invention discloses an application of dark plum fruit and an extract of dark plum fruit in control of the CRC (colorectal cancer). On the basis of the conventional efficacy of dark plum fruit, a large quantity of experiments is adopted for intensive study, an AOM-DSS (azoxymethane/dextran sodium sulfate) induced mouse model suffering from bowel disease carcinogenesis is adopted, and study results show that the dark plum fruit and the extract of the dark plum fruit can substantially improve the condition of weight loss of the model mouse in a bowel disease carcinogenesis process, can substantially improve the continuously serious symptoms such as body mass loss, loose stools, hematochezia and the like of the mouse suffering from bowel disease carcinogenesis, can substantially reduce the colonic neoplasm incidence of the mouse suffering from bowel disease carcinogenesis and has very good CRC preventing and controlling efficacy.

The invention relates to the field of biomedicines, and in particular relates to an effect and a mechanism of extract of root of Hainan devilpepper on dextran sulfate sodium colitis in mice, and the extract can interfere with signaling pathways of NF-kB and MAPKs. The extract is obtained by drying the root of Hainan devilpepper at 40 DEG C, filtering with a 0.7% ammonium oxalate solution for extraction, centrifuging residue, adjusting pH to 4.40 with HCL, again centrifuging, precipitating the residue with ethanol, and drying after centrifugation.

The invention relates to a preparation method and application of a 'baicalin-berberine' compound. First, baicalin and berberine are prepared into a yellow floccule through a heating method, and the 'baicalin-berberine' compound is obtained through centrifugation and drying. The compound is uniform in color and luster and lower in toxicity. Compared with a crude drug (berberine) and a physical blend, the compound can remarkably mask the bitter taste of the berberine. The better anti-inflammatory activity better than that of the crude drug can be shown in an acute ulcerative colitis (UC) model mouse induced by 4% dextran sodium sulfate (DSS).

The invention discloses a building method for a chicken enteritis model. The method comprises the following steps of (1) dissolving dextran sulfate sodium with a molecular weight of 36-50kDa in chicken drinking water to prepare 0.75-2.5% by weight of a dextran sulfate sodium solution, wherein the dextran sulfate sodium solution is used immediately after being prepared; (2) selecting a 14-18-day-age healthy quick-growth chicken as an object for building the chicken enteritis model; and (3) feeding the selected quick-growth chicken in a chicken house, and enabling the chicken to freely drink the dextran sulfate sodium solution prepared in the step (1) for more than 10 days. The building method for the chicken enteritis model is simple and convenient in operation; the effective dose range of the dextran sulfate sodium solution is wide, so that enteritis models of different pathological degrees can be built; and the method can be suitable for large-scale popularization and application in experiments.

The invention provides a starch-based capsule coat, which is prepared from the following raw materials in percentage by mass: 40-70wt% of anionic/cationic starch, 20-50wt% of a natural product, less than or equal to 10wt% of a plasticizer and the balance of water; the charge of the natural product is opposite to that of the anionic/cationic starch; the natural product comprises at least one of chitosan, carboxymethyl cellulose, sodium alginate, polylysine, dextran, dextran sodium sulfate and sulfonated cellulose. According to the invention, the anionic/cationic starch with charges and the natural product with opposite charges are compounded, the polyelectrolyte material can be formed under the electrostatic interaction, the acting force of the electrostatic interaction of the polyelectrolyte material is far stronger than that of hydrogen bonds and intermolecular interaction, and the polyelectrolyte material has an aggregation effect, so that the starch-based capsule coat has excellent mechanical properties.

The invention provides application of caffeic acid 3,4-dyhydroxy phenethyl ester (CADPE) to preparing a medicine for preventing colorectal cancer. The medicine is prepared from CADPE as an active component and a pharmaceutically acceptable carrier. The CAPDE is capable of effectively preventing early-stage occurrence of ICR (Institute for Cancer Research) mouse colorectal cancer induced by 1,2-dimethylhydrazine (DMH) and dextran sulphate sodium salt, has no conspicuous toxicity, and has the function mechanisms of inhibiting inflammatory cell invasion and infiltration and inhibiting NF-KappaB expression in monocyte, inhibiting expression of beta-catenin in aberrant crypt, reducing expression of cell proliferin PCNA and Cyclin D1, an anti-apoptoasis protein surviving and a cancer gene c-Myc,and inhibiting tumor vessel proliferation. Novel treatment means are provided for clinical prevention and treatment on colorectal cancer.

The invention provides an application of modified nano iron oxide in preparation of a medicine for preventing and/or treating inflammatory bowel diseases. The modified nano iron oxide is gamma-Fe2O3 nano particles, positive electricity modified gamma-Fe2O3 nano particles, negative electricity modified gamma-Fe2O3 nano particles or polymer modified gamma-Fe2O3 nano particles. Different modifications are carried out on the nano iron oxide, so that the surfaces of the iron oxide nanoparticles have different charges and potential differences, the purpose of adsorbing different inflammatory proteins in intestinal tracts is achieved, the nano iron oxide adsorbing the inflammatory proteins is discharged out of a body, and the purpose of improving or relieving intestinal diseases is achieved. Experimental results show that the nano iron oxide with different modifications can significantly improve weight loss, disease index increase, colon bleeding, colon shortening, colonic mucosa hyperplasia and colitis response in a dextran sodium sulfate induced inflammatory bowel disease mouse model, so that the inflammatory bowel disease is treated.

The invention discloses an application of dehydrolovastatin to preparation of an anti-inflammatory bowel disease medicament. The prevention and control actions and the action mechanism of the dehydrolovastatin on a mouse inflammatory bowel disease induced by dextran sulfate sodium are disclosed for the first time through tests of building a mouse acute inflammatory bowel disease model, observing the treatment effect of the dehydrolovastatin on the inflammatory bowel disease, and the like. The dehydrolovastatin significantly inhibits the levels of proinflammatory factors TNF-alpha, IL-6 and IL-17 by inhibiting an NF-kappa B signal path, raises the level of an anti-inflammatory factor IL-10, and plays a role in preventing the mouse inflammatory bowel disease induced by 4-percent DSS (Dextran Sulfate Sodium Salt).

The invention discloses an application of total saponins of panax japonicus in preparation of ulcerative colitis resisting medicines. According to the application, the prevention and treatment action and action mechanism of the total saponins of panax japonicus to dextran sulfate sodium induced mouse ulcerative colitis are researched through a series of tests, i.e., extracting the total saponins of panax japonicus, carrying out an acute toxicity test on the total saponins of panax japonicus, modeling a mouse acute ulcerative colitis model and observing the therapeutic action of the total saponins of panax japonicus on ulcerative colitis, and the influence on NF-[kappa]B and PPAR-gamma signal channels caused by the total saponins of panax japonicus is disclosed for the first time. The total saponins of panax japonicus have the effects of treating both symptoms and root causes and being safe and effective during the treatment of the ulcerative colitis.

The invention provides application of an MG53/MG53 mutant-containing composition in preparation of a drug for preventing and treating the inflammatory bowel disease. The mutant is non-polar amino acidalanine mutated from a serine site in the Coiled-coil structural domain of MG53. A mouse ulcerative colitis model is built through induction of dextran sulfate sodium (DSS); 5-aminosalicylic acid (5-ASA) is used as a positive drug for contrast; evaluation of a disease activity index (DAI), the length of a colon, a weight change and pathological changes of a colon tissue verifies that the composition has an obvious inhibition effect on the DSS-induced colitis.

The invention belongs to the field of medicines, and particularly relates to application of lycium barbarum glycopeptide in preparation of medicines for preventing or treating inflammatory bowel diseases. Experimental results of a dextran sodium sulfate (DSS)-induced mouse acute ulcerative colitis model show that the Chinese wolfberry glycopeptide can significantly advance the chronic remission period, significantly alleviate the acute colitis symptom, effectively reduce inflammatory response, and show an obvious anti-inflammatory effect. The experimental results show that the lycium barbarum glycopeptide as a traditional Chinese medicinal material extraction product can be effectively used for preventing and treating the inflammatory bowel disease, has the prospect of being developed into the medicine for preventing and treating the inflammatory bowel disease, provides more treatment choices for clinically preventing or treating the inflammatory bowel disease, and has important social benefits and economic values.

The invention relates to an application of Babaodan in preparation of a medicine for delaying occurrence and development of colitis-related colon cancer. Experimental results show that the eight-treasure pill can effectively slow down occurrence and development of azomethane oxide/dextran sodium sulfate induced colitis-related colon cancer. Meanwhile, HE staining results of the liver and the spleen show that compared with a blank control group, obvious histopathologic changes cannot be caused to the liver and the spleen after the mouse takes the eight-treasure pill for a long time, and the eight-treasure pill does not have obvious toxicity to the mouse after the mouse takes the eight-treasure pill for a long time.

The invention discloses modified sodium humate and a preparation method and application thereof. An enteritis model mouse with obvious small intestine inflammation is obtained; Kunming mice drink distilled water containing 3-4% of dextran sodium sulfate for 3-5 days, then 13-15 days later, Kunming mice drink 0.3-0.5% of modified sodium humate aqueous solution and 108 cfu/mL of escherichia coli K88bacterial liquid, alternating is conducted every other day, and an enteritis model is established and treated for 18 days in total; secondly, a sodium humate modification process is controlled; modified sodium humate with a specific molar ratio of phenolic hydroxyl to carboxyl is obtained; the preparation method mainly comprises the following steps of: weighing 100g of humic acid mineral powder with humic acid mass content of 45%, 6-12g of sodium hydroxide and 3-6g of sodium thiosulfate, adding 1000g of distilled water, stirring at 60-130 r/min, reacting at 80-120 DEG C for 60-120 minutes, and centrifuging at 4,200 r/min for 10 minutes; and putting a supernatant into a stainless steel tray, and drying in a drying oven at 80-180 DEG C until the weight is constant, thereby obtaining the modified sodium humate product.